Diverse B-cell tumors associated with t(14;19)(q32;q13)/<i>IGH</i>::<i>BCL3</i> identified by G-banding and fluorescence <i>in situ</i> hybridization
-
- Ohno Hitoshi
- Tenri Institute of Medical Research, Tenri Hospital, Tenri, Japan,
-
- Maekawa Fumiyo
- Tenri Institute of Medical Research, Tenri Hospital, Tenri, Japan,
-
- Hayashida Masahiko
- Tenri Institute of Medical Research, Tenri Hospital, Tenri, Japan,
-
- Nakagawa Miho
- Tenri Institute of Medical Research, Tenri Hospital, Tenri, Japan,
-
- Fukutsuka Katsuhiro
- Tenri Institute of Medical Research, Tenri Hospital, Tenri, Japan,
-
- Matsumura Mitsuko
- Tenri Institute of Medical Research, Tenri Hospital, Tenri, Japan,
-
- Takeoka Kayo
- Tenri Institute of Medical Research, Tenri Hospital, Tenri, Japan,
-
- Maruyama Wataru
- Department of Hematology, Tenri Hospital, Tenri, Japan,
-
- Ukyo Naoya
- Department of Hematology, Tenri Hospital, Tenri, Japan,
-
- Sumiyoshi Shinji
- Department of Diagnostic Pathology, Tenri Hospital, Tenri, Japan,
-
- Tanaka Yasuhiro
- Department of Hematology, Shinko Hospital, Tenri, Japan,
-
- Haga Hironori
- Department of Diagnostic Pathology, Graduate School of Medicine, Kyoto University, Tenri, Japan
抄録
<p>We characterized 5 B-cell tumors carrying t(14;19)(q32;q13) that creates the IGH::BCL3 fusion gene. The patients’ ages ranged between 55 and 88 years. Two patients presented with progression or recurrence of B-cell chronic lymphocytic leukemia (B-CLL)/small lymphocytic lymphoma (SLL), two with diffuse large B-cell lymphoma (DLBCL) of non-germinal center B-like phenotype, and the remaining one with composite angioimmunoblastic T-cell lymphoma and Epstein-Barr virus-positive DLBCL. The presence of t(14;19)(q32;q13) was confirmed by fluorescence in situ hybridization (FISH), showing colocalization of 3′ IGH and 3′ BCL3 probes on der(14)t(14;19) and 5′ BCL3 and 5′ IGH probes on der(19)t(14;19). One B-CLL case had t(2;14)(p13;q32)/IGH::BCL11A, and 2 DLBCL cases had t(8;14)(q24;q32) or t(8;11;14)(q24;q11;q32), both of which generated IGH::MYC by FISH, and showed nuclear expression of MYC and BCL3 by immunohistochemistry. The IGH::BCL3 fusion gene was amplified by long-distance polymerase chain reaction in 2 B-CLL/SLL cases and the breakpoints occurred immediately 5′ of BCL3 exon 1 and within the switch region associated with IGHA1. The 5 cases shared IGHV preferentially used in B-CLL cells, but the genes were unmutated in 2 B-CLL/SLL cases and significantly mutated in the remaining 3. B-cell tumors with t(14;19)(q32;q13) can be divided into B-CLL/SLL and DLBCL groups, and the anatomy of IGH::BCL3 in the latter may be different from that of the former.</p>
収録刊行物
-
- Journal of Clinical and Experimental Hematopathology
-
Journal of Clinical and Experimental Hematopathology 64 (1), 21-31, 2024
一般社団法人 リンパ網内系学会